Another study conducted by D’Andrea et al. [13] containing a large sample size of 144,614 adults with type 2 diabetes (mean age 62 years, 54% male), initiating treatment with sodium-glucose cotransporter 2 (SGLT2) inhibitors showed promising results in decreasing the risk of cardiovascular diseases [41,42]. The findings of this study highlight the potential of SGLT2 inhibitors in reducing cardiovascular risks in patients with type 2 diabetes. This evidence concerns the gene SLC5A2 and cardiovascular disorder.